COVID-19 – long-term complications in children

Short description

New ways to prevent and treat severe illness in children with COVID-19, reducing impact of the disease on young lives

Description

Children and adults respond differently to infection with SARS-CoV-2, the virus that causes COVID-19. Thankfully, most children do not experience serious symptoms, but the few who are admitted into hospital with severe disease have a much wider range of symptoms than adults – a rare condition known as Paediatric Multisystem Inflammatory Syndrome (PIMS).

The research team is aiming to improve understanding of the underlying biology behind why COVID-19 affects children and adults so differently.

Adults with severe COVID-19 generally have breathing difficulties and lung failure, but children can experience a much wider range of symptoms including vomiting, diarrhoea, tummy pain and headache – suggesting there may be more widespread inflammation compared to adults. This widespread inflammation seen in children with severe disease is known PIMS and usually occurs several weeks after infection.

The researchers aim to identify biological factors that can influence a child’s risk of severe COVID-19 and/or long-term complications from the illness that may affect their quality of life.

Findings could lead to early, personalised treatment for children who are severely affected with COVID-19, giving them the best chance of a full and rapid recovery.

The data generated in this study is closely aligned with other national and international studies – and will provide an important resource for researchers working on current and future pandemics.

Target country

Global

Project type

  • Healthcare
  • Research

Support needed

  • Other

What we need help with

This research will cost £174,358 and we are looking for partner funders

Best way to get in touch

Email ttennant@action.org.uk

Project status

  • In Progress